A Phase I/II Study of JR-141 (Idursulfase) in Patients With Mucopolysaccharidosis Type II
Phase of Trial: Phase I/II
Latest Information Update: 29 Apr 2017
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors JCR Pharmaceuticals
- 28 Apr 2017 New trial record
- 31 Mar 2017 According to a JCR Pharmaceuticals media release, top line results from this study expected early in the fourth quarter of 2017.
- 31 Mar 2017 According to a JCR Pharmaceuticals media release, first patient has been dosed.